Investigation into abnormal clotting in live patients raises concerns and prompts scientific inquiry.
-
Discussion initiated in April 2023 on abnormal clotting in live patients. • 0:36
-
Anonymously shared observations of abnormal clotting in live patients sparked further interest. • 2:01
-
Scientists from South Africa and the USA are actively researching abnormal clotting phenomena. • 3:00
-
Live clots extracted from patients revealed shocking sizes and implications for survival. • 5:08
-
Challenges in degrading massive clots and treatment strategies discussed. • 6:40
Investigation into spontaneous formation of microclots in COVID-19 patients and potential implications.
-
Study on microclots formation in COVID-19 patients began in 2020. • 7:26
-
Discovery of amalo clots forming spontaneously without thrombin in lab. • 9:35
-
Amalo clots identified in blood samples of COVID-19 patients. • 10:09
-
Attempt to induce similar clots in healthy blood using Spike protein. • 10:26
-
Association of microclots with long COVID symptoms. • 10:45
-
Research paper review on characteristics and dangers of microclots. • 11:03
-
Explanation of fibrin clot formation and breakdown process. • 11:46
-
Focus on understanding differences in amalo clots within the clotting Cascade. • 12:11
Formation of abnormal blood clots in COVID patients due to interactions of inflammatory molecules and spike proteins.
Discussion on the formation of microclots, biomarkers, and potential diagnostic tools for identifying different types of clots.
-
Microclots detected in thrombitesting raise concerns and are correlated with biomarkers like TGF beta 1. • 18:03
-
Elevated D-dimer levels may indicate breakdown of clots, suggesting a need for better clot qualification methods. • 18:11
-
Presence of fibrous clots resembling amyloid formation observed in living individuals challenges previous postmortem assumptions. • 20:06
-
Different stages of clot formation shown in images, with stage four indicating significant microclot accumulation. • 21:06
-
Macroclots attaching to endothelial cells may exhibit amyloid characteristics, impacting clinical detection methods. • 21:51
-
Microclots can pass through capillaries without fully blocking blood flow, suggesting unique structural properties. • 22:53
Discussion on the formation of significant macro clots and the role of D dier in understanding clot breakdown processes.
-
Significant macro clots pulled from healthy individuals may trap microclots, indicating a possible gradual clot formation process. • 23:44
-
D dier is found to be elevated in many patients, suggesting a potential mix of clot types transitioning to fully insoluble clots. • 27:07
-
The body’s fibrolytic system may not be critically failed in individuals with severe long Co, as they are still alive. • 28:38
Discussion on unusual blood clots found in live individuals and the need for further research and awareness.
-
Unusual blood clots observed in live individuals are concerning • 28:45
-
Need for investigating blood work and inflammatory panels of affected individuals • 29:10
-
Lack of scientific discussion and research on the phenomenon • 29:42
-
Surprise at the lack of awareness and investigation among medical professionals • 30:26
-
Questioning the occurrence of massive clots before exposure to Spike protein • 33:24
-
Physical characteristics of clots seem to have changed, affecting their breakdown • 33:53
Discussion on potential sources of Spike protein triggering clot formation in individuals post-vaccination or infection.
-
Healthy individuals may also have underlying conditions predisposing them to clot formation. • 34:18
-
Spike protein from various sources, including vaccination and persistent infection, could contribute to clotting. • 35:10
-
Study in progress to evaluate microclots in individuals with post-vaccine events like pericarditis. • 36:30
-
Concerns raised about ongoing exosome transfer of Spike proteins leading to prolonged inflammation and coagulation. • 39:05
-
Evidence of circulating Spike protein in vaccinated individuals months after vaccination. • 39:28
Discussion on potential mechanisms of clot formation in relation to Spike protein exposure.
-
Spike protein, from the virus or vaccine, acts as a magnet for every cell it comes in contact with. • 39:53
-
Importance of identifying individuals at risk for adverse effects from Spike protein exposure. • 40:21
-
Need for a balanced approach in medicine considering risk, benefits, and alternatives of interventions. • 40:29
-
Emphasis on the necessity of diagnostics, such as flow cytometry, for accurate assessment and treatment initiation. • 41:31
-
Appreciation for clinicians and researchers working towards proactive patient care in the face of emerging health challenges. • 42:25
-
Acknowledgment of the role of endothelitis and microparticle clotting in affecting various body systems. • 43:27
-
Recognition of vascular and neuroinflammation as potential consequences of clotting and endothelial damage. • 43:40
-
Development of natural compounds to reverse clotting and mitigate risks of complications. • 43:53
Exploration of alternative treatments for a unique disease, importance of scientific research, and ongoing work in South Africa.
-
Exploring safer and effective alternatives for treatment • 44:29
-
Importance of thinking outside the box for a massive disease • 44:41
-
Significance of ongoing scientific research globally • 45:28
-
Supporting scientists financially for crucial research • 45:44
-
Simple method to check for amalo f fibrin microts • 46:00
-
Continued discussions and future plans for research • 46:14